ACE-031, also known as ramatercept, is a soluble fusion protein built from the extracellular portion of the activin receptor type IIB (ActRIIB) joined to a human IgG1 antibody fragment. It works as a decoy receptor — circulating in the bloodstream and binding myostatin and related proteins before they can reach muscle cells. Myostatin is the body's primary brake on muscle growth, so neutralizing it removes a powerful inhibitory signal and allows muscle to expand.
What makes ACE-031 distinctive among myostatin-targeted compounds is its breadth. Rather than blocking myostatin alone, it intercepts multiple negative regulators of muscle mass that all signal through the same receptor, including activin A. This multi-ligand approach appears to produce more pronounced effects on lean mass and strength than blocking myostatin in isolation. Originally developed by Acceleron Pharma as a potential therapy for muscular dystrophy and other wasting conditions, ACE-031 has since become one of the most studied compounds in the myostatin-inhibition class.
ACE-031 and Muscle Mass in Healthy Subjects
The first human data on ACE-031 came from a Phase I trial in 48 healthy postmenopausal women, who received a single subcutaneous dose ranging from 0.02 to 3 mg/kg (5). At the highest dose, mean total body lean mass increased by 3.3% as measured by DXA, and thigh muscle volume increased by 5.1% on MRI — both statistically significant changes observed within 29 days of a single injection. Serum biomarkers also shifted in directions suggesting improvements in bone and fat metabolism alongside the muscle gains.
Pharmacokinetic analysis showed a linear dose-exposure relationship and a half-life of 10 to 15 days, meaning the compound persists in circulation long enough to produce sustained effects from infrequent dosing. The trial reported the compound was generally well-tolerated, with injection site redness as the most common observation.
Later work in non-human primates extended these findings, with 14 weeks of ACE-031 administration producing significant increases in lean body mass, biceps muscle fiber cross-sectional area in both type I and type II fibers, and ex vivo force production from isolated muscle (1, 3). The fact that a single small dose moved the needle in healthy humans, and that longer-term dosing amplified those changes in primates, is what drew sustained research interest to this molecule.
ACE-031 and Muscular Dystrophy
The most direct test of ACE-031's therapeutic potential came in a randomized, placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy (4). Subjects received subcutaneous injections every two to four weeks. Across the trial, treated participants showed trends toward maintenance of walking distance on the 6-minute walk test, increases in lean body mass and bone mineral density, and reductions in fat mass — though these trends did not reach statistical significance in the small cohort.
The trial was stopped after the second dosing regimen due to non-muscle adverse events: nosebleeds (epistaxis) and small dilated blood vessels near the skin surface (telangiectasias). These appear to reflect off-target effects of blocking ActRIIB ligands beyond muscle tissue, since the receptor is also involved in vascular regulation. The muscle-specific findings remained encouraging enough that the broader strategy of myostatin pathway inhibition continued to be pursued, with the authors concluding that targeting this pathway is a promising therapeutic approach for muscle-wasting conditions.
ACE-031 and the Myostatin Pathway
The mechanism behind ACE-031's effects is well-characterized at the molecular level. Myostatin and activin A normally bind to ActRIIB on the surface of muscle cells, triggering a signaling cascade that limits muscle protein synthesis and suppresses the growth and fusion of muscle precursor cells. By acting as a soluble version of that same receptor, ACE-031 sequesters these ligands in circulation before they reach the cell surface — effectively cutting off the inhibitory signal.
This releases muscle from its default growth restraint. The result, observed consistently across studies, is hypertrophy of existing muscle fibers (rather than the formation of new fibers) along with increased contractile force per unit of muscle (1, 3). Both type I (slow-twitch, endurance-oriented) and type II (fast-twitch, power-oriented) fibers respond, suggesting the pathway operates broadly across muscle types.
A separate research application has used ACE-031 instrumentally — injecting it locally to induce muscle hyperplasia as a tool to study how muscle bulk affects intracranial pressure and cerebrospinal fluid dynamics (6). That a single peptide can reliably grow targeted muscle groups is itself a useful demonstration of its mechanistic specificity.